Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E11.31 EPS (ttm)9.53 Insider Own0.50% Shs Outstand1.47B Perf Week2.33%
Market Cap158.18B Forward P/E9.27 EPS next Y11.62 Insider Trans-19.01% Shs Float1.46B Perf Month-8.58%
Income15.04B PEG0.68 EPS next Q2.82 Inst Own83.50% Short Float1.28% Perf Quarter-5.18%
Sales29.19B P/S5.42 EPS this Y306.10% Inst Trans-2.51% Short Ratio1.76 Perf Half Y4.18%
Book/sh11.06 P/B9.75 EPS next Y-0.45% ROA42.70% Target Price126.72 Perf Year0.61%
Cash/sh5.87 P/C18.37 EPS next 5Y16.73% ROE96.30% 52W Range85.64 - 123.37 Perf YTD14.76%
Dividend1.72 P/FCF9.20 EPS past 5Y39.10% ROI44.80% 52W High-12.64% Beta0.84
Dividend %1.60% Quick Ratio1.80 Sales past 5Y28.80% Gross Margin86.50% 52W Low25.85% ATR4.19
Employees7000 Current Ratio2.00 Sales Q/Q26.20% Oper. Margin64.40% RSI (14)41.20 Volatility6.56% 3.19%
OptionableYes Debt/Eq0.75 EPS Q/Q32.70% Profit Margin51.50% Rel Volume1.01 Prev Close107.99
ShortableYes LT Debt/Eq0.73 EarningsJul 28 AMC Payout4.30% Avg Volume10.64M Price107.78
Recom1.90 SMA20-5.02% SMA50-6.73% SMA2001.38% Volume10,746,863 Change-0.19%
Jul-29-15Reiterated RBC Capital Mkts Outperform $120 → $130
Jul-29-15Reiterated Piper Jaffray Overweight $131 → $134
Jul-29-15Reiterated Oppenheimer Outperform $86 → $120
Jul-29-15Reiterated Needham Buy $120 → $125
Jul-29-15Reiterated Maxim Group Buy $127 → $129
Jul-29-15Reiterated Deutsche Bank Buy $125 → $135
Jul-29-15Reiterated Barclays Overweight $125 → $130
Jul-24-15Reiterated Piper Jaffray Overweight $120 → $131
Jun-23-15Reiterated Argus Buy $130 → $150
May-01-15Reiterated RBC Capital Mkts Outperform $118 → $120
May-01-15Reiterated Piper Jaffray Overweight $116 → $120
Feb-04-15Reiterated RBC Capital Mkts Outperform $125 → $118
Dec-23-14Reiterated Deutsche Bank Buy $142 → $125
Dec-09-14Reiterated Argus Buy $110 → $130
Oct-29-14Reiterated RBC Capital Mkts Outperform $115 → $125
Oct-13-14Reiterated FBR Capital Outperform $125 → $130
Sep-25-14Reiterated Needham Buy $95 → $120
Aug-22-14Reiterated RBC Capital Mkts Outperform $102 → $115
Aug-15-14Initiated FBR Capital Outperform $125
Aug-11-14Reiterated Argus Buy $90 → $110
Aug-29-15 03:14PM  The Stocks That Got Hit The Hardest In The Recent Correction
Aug-28-15 04:54PM  The Top 3 Medtech Buyout Rumors This Week at Investor's Business Daily
04:40PM  Pfizer (PFE) Gains on Label Expansion Efforts for Ibrance
04:00PM  Exelixis Up on Swiss Approval of Advanced Melanoma Drug
03:34PM  Gilead & Amgen Account for Nearly 75% of the Biotech Profit Pool at Barrons.com
10:57AM  27 Stocks to Buy After the Pullback at Barrons.com
07:47AM  More Bargain Hunting: Three Places to Find the Fattest Dividends at Forbes
Aug-27-15 01:56PM  Best way to play the market
11:06AM  Biogen And Gilead Sciences Catch The Eye Of Short Sellers
11:02AM  'We See Opportunity in Biogen, Gilead and Regeneron,' Morgan Stanley Says at Barrons.com
Aug-26-15 05:00PM  Results From the AMBITION Study of First-Line Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension Published in The New England Journal of Medicine Business Wire
09:46AM  Celldex (CLDX) Shows Strength: Stock Adds 8.2% in Session
08:55AM  Short Sellers Become More Focused in Major Biotechs at 24/7 Wall St.
08:40AM  What Makes CoLucid Pharmaceuticals (CLCD) a Strong Sell?
Aug-25-15 06:41PM  4 Notable Stocks Still Green After Late Tuesday Sell-Off
05:31PM  Nasdaq Slips into Correction: 4 Stocks Stand Tall
03:36PM  U.S. Stocks Rally, But Is Now Time to Buy? at TheStreet
03:06PM  Gilead Leads 4 Drugmakers In Top Sector Performers at Investor's Business Daily
12:15PM  Bouncing Biotech? 3 Stocks To Buy at Motley Fool
11:25AM  AMAG is a Hidden Biotech Gem That is Exploding
10:58AM  Is the bull market back? Not so fast: Insana at CNBC
10:42AM  Gilead: Waiting Is the Best Part at The Wall Street Journal
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, DSW, Cardtronics and CECO Environmental
08:51AM  Epizyme (EPZM) Shows Strength: Stock Adds 9.6% in Session
07:38AM  An Inside Look at Biotech Investor Pros Dealing With Market Meltdown at TheStreet
Aug-24-15 05:00PM  Trading the historic market dip: 6 stocks to buy
03:25PM  Winners since last correction
02:25PM  Biotechs rally back
12:56PM  Top trades for the 2nd half: Correction territory
12:25PM  6 Things to Know About a Stock Market Correction
12:19PM  6 things you should know about a stock market correction at USA TODAY
12:17PM  US 'big four' biotechs lead sector tumble into bear market at Financial Times
10:27AM  Stock Futures Plunge: 4 Value Stocks Brokers Love Right Now
08:44AM  Arena Pharmaceuticals (ARNA) Rises: Stock Adds 5.7% in Session
08:37AM  Raptor Pharmaceuticals (RPTP) in Focus: Stock Adds 5.8%
06:53AM  Biotech blues despite 12% gain YTD
06:15AM  Biogen Pipeline Doesn't Justify High Valuation at Barrons.com
Aug-23-15 05:25PM  Your Monday plan: Buy Apple, sell Apple at CNBC
Aug-22-15 09:12AM  Bad News for Hepatitis C Patients: Your Treatment Costs May Be Higher Than Expected at Motley Fool
01:34AM  Intuit Slims Down and Fattens Payouts at Barrons.com
Aug-21-15 04:30PM  Is Valeant's (VRX) $1B Buy of Addyi Maker a Prudent Move? -6.28%
04:13PM  How Big Biotech Spents It's Money at Barrons.com
03:34PM  Gilead Sciences: Hep-C Prescriptions Still Slowing at Barrons.com
03:25PM  Gilead's EU Regulatory Application for HIV Drug Validated
01:15PM  Why Medivation is a Stunning Biotech Opportunity
08:39AM  Falling Earnings Estimates Signal Weakness Ahead for Alexion Pharmaceuticals (ALXN)
03:06AM  Will Orkambi Be a Game Changer for Vertex?
Aug-20-15 04:30PM  European Medicines Agency Validates Gileads Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment Business Wire
02:30PM  Illumina (ILMN) Creates Helix to Encourage Genomics Startups
01:03PM  Key Financial Ratios to Analyze Biotech Companies at Investopedia
11:06AM  Regeneron Outperforms with Better 2Q15 Results
09:48AM  How to Trade 5 Big Stocks for Big Gains -- Must-See Charts at TheStreet
Aug-19-15 06:29PM  Celgene May be The Single Best Biotech in the World
04:20PM  Merck's Keytruda under FDA Review for First-Line Melanoma
07:00AM  This is the fastest growing company in the U.S. at Fortune
07:00AM  This is the fastest growing company in the U.S.
Aug-18-15 08:34PM  Will Large-Cap Stock Funds Continue Their Run? at Investor's Business Daily
03:20PM  3 Stocks Warren Buffett and Peter Lynch Should Own at TheStreet
01:23PM  Five Reasons to Buy Biogen at Barrons.com
12:52PM  Unusual Activity: Gilead
11:21AM  3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever at Motley Fool
09:56AM  IBB Drops Out of the 50-Day and 20-Day Moving Averages
Aug-17-15 07:05PM  Horizon Pharmas Specialty Business Unit in 2Q15
06:30PM  Facebook, EBay, Google Flex Renewed Tech Strength at Investor's Business Daily
05:09PM  Better Dividend Stock: Gilead Sciences Inc. vs. Amgen Inc. at Motley Fool
03:30PM  Onconova Files IND Application for Rigosertib, Shares Jump
03:25PM  SYRX: Leveraging its New Technologies to Cross-Promote Services and Generate Synergies
03:06PM  Why Achillion Pharmaceuticals Jumped 10% Today at Motley Fool
01:45PM  Opposing viewpoints on the existence (or not) of a 'bubble' in biotech at bizjournals.com
11:08AM  Westport Asset Management Sells Bulk of Two Stakes
Aug-16-15 12:43PM  Drug pricing comes under the microscope at Financial Times
Aug-15-15 08:39AM  3 Numbers Show Why Gilead Sciences Inc. Is in a Great Position Today at Motley Fool
Aug-14-15 02:40PM  AMGN vs. GILD: The Battle of the Large Cap Biotech Stock
02:30PM  Integra Closes TEI Buyout to Grow in Regenerative Wound Care
02:15PM  Myriad: Medicare Coverage for Prolaris Prostrate Cancer Test
01:35PM  Biotech still great growth sector: Pro
12:54PM  Is It Time For Gilead Sciences To Buy Achillion?
09:11AM  Celgene Vs. Gilead: Vetting for the Best Biopharma at Investopedia
Aug-13-15 04:36PM  Abiomed, Cambrex Show Why Bigger Isn't Always Better at Investor's Business Daily
01:30PM  8 Great Stocks to Own for Retirement at Kiplinger
01:04PM  GILEAD SCIENCES INC Financials
11:42AM  Payers Set To Play Hardball On PCSK9 Pricing: RBC at Investor's Business Daily
11:34AM  Gilead Sciences: Why Hepatitis-C Sales Could Fall Short at Barrons.com
09:25AM  Myriad Genetics (MYGN) Jumps: Stock Moves 6.8% Higher
08:04AM  Is Gilead Sciences Biotech's Biggest Bargain? at Motley Fool
Aug-12-15 04:05PM  Pluristem (PSTI) Provides Update on PLX-PAD Cells in Japan
02:35PM  BioScrip's Strategic Plans Offer Hope, Margin Concerns Stay
08:55AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
06:53AM  Bob Doll cautious, says 'stay domestic'
Aug-11-15 12:45PM  A misguided attempt to rein in drug costs in Massachusetts at bizjournals.com
11:06AM  Why Did Gilead Sciences Stock Rise?
10:30AM  Repros Incurs Narrower Y/Y Loss in Q2, Pipeline in Focus - Analyst Blog
08:43AM  Gilead Sciences Stock: 3 Reasons Why It Is a Top Choice for Growth Investors - Tale of the Tape
Aug-10-15 02:40PM  CVS, Express Scripts Pick Drugs to Restrict; Did Gilead's Sovalidi Make the Cut? at Barrons.com
01:31PM  Biotech: Is This the End of the Rally? at Barrons.com
11:43AM  Biotech Stocks Rise Due to a Stable Market: July 31 Week
Aug-09-15 09:02AM  3 Biotech Stocks to Buy in August at Motley Fool
Aug-08-15 09:02AM  Did Gilead Sciences Just Give Wall Street a Huge Head Fake? at Motley Fool
Aug-07-15 08:12PM  10-Q for Gilead Sciences, Inc. at Company Spotlight
05:58PM  Sarepta Posts Narrower-than-Expected Loss in Q2, Shares Up - Analyst Blog
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with Bristol-Myers Squibb Company, Janssen R&D Ireland, and Japan Tobacco Inc. to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CChairman and CEOAug 25Sale105.17133,21314,009,8720Aug 26 05:51 PM
Cogan John FrancisDirectorAug 03Option Exercise20.7115,000310,57559,309Aug 04 05:01 PM
Alton Gregg HEVP, Corp & Med AffairsAug 03Option Exercise23.7615,000356,325154,422Aug 04 05:08 PM
MARTIN JOHN CChairman and CEOAug 03Option Exercise14.50150,0002,175,3754,364,492Aug 04 05:07 PM
Carter Paul RutherfordEVP Commercial OpsAug 03Option Exercise26.995,000134,95053,783Aug 04 05:08 PM
Cogan John FrancisDirectorAug 03Sale120.0015,0001,800,00044,309Aug 04 05:01 PM
Alton Gregg HEVP, Corp & Med AffairsAug 03Sale119.1117,0002,024,870137,422Aug 04 05:08 PM
MARTIN JOHN CChairman and CEOAug 03Sale119.18150,00017,876,6194,214,492Aug 04 05:07 PM
Carter Paul RutherfordEVP Commercial OpsAug 03Sale119.185,000595,92048,783Aug 04 05:08 PM
Carter Paul RutherfordEVP Commercial OpsJul 31Option Exercise0.002,500050,132Aug 04 05:00 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJul 15Option Exercise21.5870,0001,510,250235,168Jul 17 03:57 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJul 15Sale118.2066,2617,832,152168,907Jul 17 03:57 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJul 07Sale119.393,739446,400165,168Jul 17 03:57 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Option Exercise26.993,00080,97050,632Jul 06 04:00 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Option Exercise23.7615,000356,325156,422Jul 06 04:01 PM
MARTIN JOHN CChairman and CEOJul 01Option Exercise14.50150,0002,175,3754,364,492Jul 06 04:02 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Sale118.243,000354,72947,632Jul 06 04:00 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Sale116.7317,0001,984,446139,422Jul 06 04:01 PM
MARTIN JOHN CChairman and CEOJul 01Sale116.46150,00017,469,6614,214,492Jul 06 04:02 PM
Cogan John FrancisDirectorJun 26Option Exercise14.3412,000172,08056,309Jun 30 07:32 PM
Cogan John FrancisDirectorJun 26Sale120.1327,0003,243,42144,309Jun 30 07:32 PM
Carter Paul RutherfordEVP Commercial OpsJun 18Option Exercise26.9910,000269,90057,632Jun 22 04:17 PM
Carter Paul RutherfordEVP Commercial OpsJun 18Sale120.0010,0001,200,02547,632Jun 22 04:17 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 15Option Exercise21.5870,0001,510,250235,168Jun 17 07:25 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 15Sale117.6770,0008,237,002165,168Jun 17 07:25 PM
MILLIGAN JOHN FPresident and COOJun 08Option Exercise14.50100,0001,450,2501,129,108Jun 10 01:03 PM
MILLIGAN JOHN FPresident and COOJun 08Sale114.05100,00011,405,4131,029,108Jun 10 01:03 PM
MARTIN JOHN CChairman and CEOJun 01Option Exercise14.50150,0002,175,3754,405,876Jun 03 06:07 PM
Alton Gregg HEVP, Corp & Med AffairsJun 01Option Exercise23.7115,000355,647158,422Jun 03 06:07 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Option Exercise34.713,000104,12050,632Jun 03 06:07 PM
MARTIN JOHN CChairman and CEOJun 01Sale113.95150,00017,092,3444,255,876Jun 03 06:07 PM
Alton Gregg HEVP, Corp & Med AffairsJun 01Sale113.6417,0001,931,891141,422Jun 03 06:07 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Sale113.093,000339,27847,632Jun 03 06:07 PM
Carter Paul RutherfordEVP Commercial OpsMay 15Option Exercise67.786,000406,68753,632May 19 07:24 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 15Option Exercise21.3470,0001,493,550235,168May 19 07:25 PM
Alton Gregg HEVP, Corp & Med AffairsMay 15Option Exercise19.2025,000479,947168,422May 19 07:25 PM
Carter Paul RutherfordEVP Commercial OpsMay 15Sale110.006,000660,02047,632May 19 07:24 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 15Sale109.4570,0007,661,533165,168May 19 07:25 PM
Alton Gregg HEVP, Corp & Med AffairsMay 15Sale110.0125,0002,750,210143,422May 19 07:25 PM
Carter Paul RutherfordEVP Commercial OpsMay 10Option Exercise0.005,000050,439May 12 06:02 PM
MILLIGAN JOHN FPresident and COOMay 07Option Exercise14.50100,0001,450,2501,129,108May 11 08:24 PM
MILLIGAN JOHN FPresident and COOMay 07Sale101.00100,00010,100,1621,029,108May 11 08:24 PM
Whitley Richard JamesDirectorMay 05Option Exercise19.6321,720426,36437,361May 07 05:14 PM
MARTIN JOHN CChairman and CEOMay 01Option Exercise14.50150,0002,175,3754,405,876May 05 05:47 PM
Washington Robin LEVP, CFOMay 01Option Exercise29.7016,842500,13044,566May 05 07:38 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Option Exercise19.0910,000190,850155,422May 05 07:38 PM
Carter Paul RutherfordEVP Commercial OpsMay 01Option Exercise80.652,000161,30047,439May 05 04:23 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Sale104.0712,0001,248,871143,422May 05 07:38 PM
Washington Robin LEVP, CFOMay 01Sale105.0616,8421,769,40527,724May 05 07:38 PM
MARTIN JOHN CChairman and CEOMay 01Sale104.95150,00015,742,4914,255,876May 05 05:47 PM
Carter Paul RutherfordEVP Commercial OpsMay 01Sale103.182,000206,36545,439May 05 04:23 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 15Option Exercise20.7470,0001,451,800235,168Apr 17 02:23 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 15Sale103.8470,0007,268,627165,168Apr 17 02:23 PM
Alton Gregg HEVP, Corp & Med AffairsApr 08Option Exercise19.095,00095,425150,422Apr 09 04:40 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Option Exercise80.651,00080,65046,439Apr 09 04:40 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Sale100.001,000100,00045,439Apr 09 04:40 PM
Alton Gregg HEVP, Corp & Med AffairsApr 08Sale100.005,000500,000145,422Apr 09 04:40 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Option Exercise80.651,00080,65046,439Apr 03 05:24 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Option Exercise19.095,00095,425152,422Apr 03 05:24 PM
MARTIN JOHN CChairman and CEOApr 01Option Exercise14.50150,0002,175,3754,405,876Apr 03 05:24 PM
MARTIN JOHN CChairman and CEOApr 01Sale96.74150,00014,511,4634,255,876Apr 03 05:24 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale96.537,000675,715145,422Apr 03 05:24 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Sale98.041,00098,04445,439Apr 03 05:24 PM
Whitley Richard JamesDirectorMar 02Option Exercise26.995,000134,95020,641Mar 03 04:12 PM
Alton Gregg HEVP, Corp & Med AffairsMar 02Option Exercise19.0910,000190,850159,422Mar 04 07:49 PM
MARTIN JOHN CChairman and CEOMar 02Option Exercise14.50150,0002,175,3754,405,876Mar 04 07:48 PM
Carter Paul RutherfordEVP Commercial OpsMar 02Option Exercise80.652,000161,30047,439Mar 04 07:49 PM
Carter Paul RutherfordEVP Commercial OpsMar 02Sale104.182,000208,36445,439Mar 04 07:49 PM
MARTIN JOHN CChairman and CEOMar 02Sale103.51150,00015,526,2454,255,876Mar 04 07:48 PM
Alton Gregg HEVP, Corp & Med AffairsMar 02Sale103.6312,0001,243,615147,422Mar 04 07:49 PM
Whitley Richard JamesDirectorMar 02Sale103.435,000517,13615,641Mar 03 04:12 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 17Option Exercise16.4070,0001,147,650235,168Feb 19 06:42 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 17Sale103.0170,0007,210,740165,168Feb 19 06:42 PM
WOLD OLSEN PERDirectorFeb 06Buy99.9210,000999,15088,173Feb 10 04:30 PM
MARTIN JOHN CChairman and CEOFeb 02Option Exercise14.50150,0002,175,3754,272,987Feb 04 08:15 PM
Washington Robin LEVP, CFOFeb 02Option Exercise25.1433,192834,58683,024Feb 04 08:52 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 02Option Exercise19.0910,000190,850123,694Feb 04 08:51 PM
Carter Paul RutherfordEVP Commercial OpsFeb 02Option Exercise80.652,000161,30036,308Feb 04 08:52 PM
Whitley Richard JamesDirectorFeb 02Option Exercise26.995,000134,95020,641Feb 04 04:04 PM
Whitley Richard JamesDirectorFeb 02Sale105.675,000528,35815,641Feb 04 04:04 PM
Carter Paul RutherfordEVP Commercial OpsFeb 02Sale106.152,000212,31034,308Feb 04 08:52 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 02Sale105.7312,0001,268,719111,694Feb 04 08:51 PM
Washington Robin LEVP, CFOFeb 02Sale105.3833,1923,497,66249,832Feb 04 08:52 PM
MARTIN JOHN CChairman and CEOFeb 02Sale105.43150,00015,815,2494,122,987Feb 04 08:15 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Option Exercise16.4070,0001,147,650189,302Jan 20 12:46 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Sale98.4770,0006,893,083119,302Jan 20 12:46 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Option Exercise36.721,00036,72035,308Jan 12 03:55 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Sale100.881,000100,88134,308Jan 12 03:55 PM
MARTIN JOHN CChairman and CEOJan 05Sale96.651009,6654,122,987Jan 06 04:20 PM
Whitley Richard JamesDirectorJan 02Option Exercise26.995,000134,95020,641Jan 06 02:12 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Option Exercise19.095,00095,425120,694Jan 06 04:20 PM
MARTIN JOHN CChairman and CEOJan 02Option Exercise14.50150,0002,175,3754,272,987Jan 06 04:20 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Option Exercise40.561,00040,56035,308Jan 06 04:21 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Sale95.051,00095,05034,308Jan 06 04:21 PM
MARTIN JOHN CChairman and CEOJan 02Sale95.11149,90014,257,7224,123,087Jan 06 04:20 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Sale95.177,000666,192113,694Jan 06 04:20 PM
Whitley Richard JamesDirectorJan 02Sale95.225,000476,10015,641Jan 06 02:12 PM
Cogan John FrancisDirectorDec 22Option Exercise14.3426,000372,77568,405Dec 24 12:58 PM
Cogan John FrancisDirectorDec 22Sale95.0326,0002,470,75542,405Dec 24 12:58 PM
MILLIGAN JOHN FPresident and COODec 08Option Exercise8.01146,8231,175,3181,120,871Dec 10 05:32 PM